Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Trial Details
- NCT ID
- NCT05180097
- Phase
- PHASE2
- Sponsor
- Canadian Cancer Trials Group
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Gemcitabine
- Dexamethasone
- Cisplatin
- Brentuximab vedotin
- Pembrolizumab
- Locations (sample)
- Concord, New South Wales, Australia|-33.84722,151.10381
- Nowra, New South Wales, Australia|-34.88422,150.60036
- Wollongong, New South Wales, Australia|-34.424,150.89345
- Adelaide, South Australia, Australia|-34.92866,138.59863
- Heidelberg, Victoria, Australia|-37.75,145.06667
Key Eligibility Criteria
- History of classic Hodgkin lymphoma by histopathology and now have relapsed or refractory disease after anthracycline-containing chemotherapy and e…
- 18 years of age or greater
- ECOG performance status 0-1
- Clinically and/or radiologically measurable disease as per the Lugano 2014 classification
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →